Brand Strategist | Marketing Analyst | Researcher | Creative Director
Independent Strategy DisclosureThis independent exercise uses public information available through August 9, 2026. It was not commissioned or endorsed by Organon, Sun Pharma, NEXPLANON or any competitor.
Executive Snapshot
Following Sun Pharma’s proposed $11.75 billion acquisition of Organon, the obvious integration route was full absorption. This project tested a harder question: could Organon create more value as a protected women’s-health platform than Sun Pharma would save by absorbing it?
The Strategic Challenge
Retaining Organon would add management, marketing and governance costs. Full absorption could reduce duplication, but it could also weaken recognition, customer confidence and Organon’s position in women’s health.
The decision required evidence: when does a corporate name create enough customer and economic value to survive an acquisition?
My Role
As an independent Brand Strategist and Creative Director, I built the business and brand case from public information. I examined acquisition economics, customer needs, competitor positioning, portfolio architecture, marketing investment, governance and crisis readiness.
The Strategic Response
The recommendation was to retain Organon as an endorsed women’s-health brand under Sun Pharma, but only while it could prove its value.
Keep protects useful brand equity and stakeholder trust during integration. Prove measures commercial contribution, customer relevance, reputation, access and operational performance. Grow releases further investment only after the brand meets defined thresholds.
The model included stop rules. Organon should not be protected if retention weakened supply, access, medical quality, trust, financial control or integration performance.
NEXPLANON became the practical test case. The proposed U.S. relaunch used “Your timeline. Your talk.” to support informed contraceptive choice. A 12-month base plan and $18.5 million planning budget connected research, professional education, consumer communication, measurement and crisis preparation.
Business and Brand Value
The project reframed brand retention as a capital-allocation decision. It showed how brand equity can be protected without becoming untouchable, and how marketing investment can be governed through evidence, milestones and exit criteria.
What This Project Demonstrates
M&A brand strategy, pharmaceutical and women’s-health positioning, microeconomic analysis, brand architecture, portfolio strategy, governance, crisis planning, measurement and creative translation.
View the Strategy Documents
The reports provide the economic analysis, five-year roadmap, marketing plan, crisis system, board presentation and NEXPLANON briefs.
Download Strategy Report and other Documentation
Independent portfolio project. This analysis was not commissioned, approved or endorsed by Organon, Sun Pharma or any organization referenced. Financial figures are scenario estimates and product communications are conceptual.